Clinical Use of Biologics for CRSwNP: Implementing Strategies for Treatment Success
Released On
October 24, 2024
Expires On
October 24, 2025
Media Type
Internet
Completion Time
60 minutes
Specialty
Allergy & Immunology, Nasal Polyps, Otolaryngology, Primary Care
Topics
Allergies
Provider Statement
This activity is provided by Integrity CE, LLC.
Disclosure of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.
Credit Available
- Physicians - maximum of 1.0 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity addresses the needs of allergists, otolaryngologists, nurse practitioners, and physician assistants involved in the management of patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Program Overview
During this case-based interactive video, our esteemed faculty will discuss strategies to improve the care of patients with CRSwNP. Key topics will include patient evaluation, selection criteria for surgical or biologic treatment, and current evidence on comparative safety and efficacy of available treatments.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Effectively assess severity in patients with CRSwNP
- Select appropriate biologic or surgical treatment options for patients with CRSwNP based on available efficacy and safety data
- Implement strategies for the effective use of biologic therapies in the treatment of appropriate patients with CRSwNP and to overcome barriers to successful treatment
Faculty
Christine Franzese, MD
Professor of Clinical Otolaryngology
Director of Allergy
Department of Otolaryngology – Head and Neck Surgery
University of Missouri
Columbia, Missouri
Joseph K. Han, MD
Professor of Medicine
Chief, Division of Rhinology & Endoscopic Sinus and Skull Base Surgery
Chief, Division of Allergy
Eastern Virginia Medical School
Norfolk, Virginia
Accreditation Statement
Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Integrity CE, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts Of Interest
Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:
Christine Franzese, MD
Research Support: AstraZeneca, Eli Lilly, GlaxoSmithKline, Lyra, Regeneron, Sanofi, Upstream Bio
Speakers’ Bureau: AstraZeneca, GlaxoSmithKline, Optinose, Regeneron, Sanofi
Joseph K. Han, MD
Research Consultant: AstraZeneca, GlaxoSmithKline, Sanofi Regeneron
The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. During the period of October 24, 2024 through October 24, 2025 participants must:
- Read the learning objectives
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed posttest with a score of 66% or better and a completed activity evaluation form.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Contact Information
For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or [email protected].